Our commitment to the advancement of the cardio-metabolic sector dates back to 1988 with the introduction of the
first ACE-inhibitor combined with a diuretic. We remain committed in its advancements through the development of a
wide range of cardio-metabolic pharmaceutical products that are at the frontier of medical development, to help in
the prevention of risk factors and particularly in the treatment of hypertension.
* Please note that some brands may not be available in your market.